|Chemical and physical data|
|Molar mass||564.07 g/mol g·mol−1|
|3D model (JSmol)|
ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09 nM. It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.
- “Patent WO/2009/106982 – Indazole derivatives”.
- “Cannabinoider föreslås bli klassade som hälsofarlig vara” (in Swedish). Folkhälsomyndigheten. Retrieved 8 July 2015.